Your browser doesn't support javascript.
loading
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett, Laura; Howard, Dena R; Munir, Talha; McParland, Lucy; Oughton, Jamie B; Rawstron, Andy C; Hockaday, Anna; Dimbleby, Claire; Phillips, David; McMahon, Kathryn; Hulme, Claire; Allsup, David; Bloor, Adrian; Hillmen, Peter.
Affiliation
  • Collett L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Howard DR; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Munir T; St James' Institute of Oncology, St James' University Hospital, Leeds, UK.
  • McParland L; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Oughton JB; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. J.Oughton@leeds.ac.uk.
  • Rawstron AC; Haematological Malignancy Diagnostic Service, St James' Institute of Oncology, St James' University Hospital, Leeds, UK.
  • Hockaday A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Dimbleby C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Phillips D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • McMahon K; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Hulme C; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • Allsup D; Hull York Medical School, Department of Haematology, Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull and East Yorkshire Hospitals NHS Trust, Cottingham, UK.
  • Bloor A; Department of Haematology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK.
  • Hillmen P; St James' Institute of Oncology, St James' University Hospital, Leeds, UK.
Trials ; 18(1): 387, 2017 08 22.
Article in En | MEDLINE | ID: mdl-28830517
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Rituximab / Antineoplastic Agents, Immunological Type of study: Clinical_trials / Diagnostic_studies Country/Region as subject: Europa Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2017 Type: Article Affiliation country: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrazoles / Pyrimidines / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Rituximab / Antineoplastic Agents, Immunological Type of study: Clinical_trials / Diagnostic_studies Country/Region as subject: Europa Language: En Journal: Trials Journal subject: MEDICINA / TERAPEUTICA Year: 2017 Type: Article Affiliation country: United kingdom